Figures & data
Figure 1. Schematic overview of the effect of bacteriocin-producing probiotic Lactobacillus salivarius UCC118 and oral vancomycin on the composition of the gut microbiota at family level in diet-induced obese mice.
![Figure 1. Schematic overview of the effect of bacteriocin-producing probiotic Lactobacillus salivarius UCC118 and oral vancomycin on the composition of the gut microbiota at family level in diet-induced obese mice.](/cms/asset/5a85f959-580b-4eac-bb09-5545915ce58f/kgmi_a_10922328_f0001.gif)
Figure 2. Acetate and propionate production (µmol/g) over the 8 week intervention period in (1) lean, DIO and vancomycin-treated DIO mice and (2) DIO mice treated with the bacteriocin-producing probiotic strain L. salivarius UCC118 Bac+ (1 × 109 cfu/day) compared with DIO mice treated with a non-bacteriocin-producing derivative L. salivarius UCC118Bac- (1 × 109 cfu/day). Data represented as mean ± SEM, n = 9–10. *p < 0.05
![Figure 2. Acetate and propionate production (µmol/g) over the 8 week intervention period in (1) lean, DIO and vancomycin-treated DIO mice and (2) DIO mice treated with the bacteriocin-producing probiotic strain L. salivarius UCC118 Bac+ (1 × 109 cfu/day) compared with DIO mice treated with a non-bacteriocin-producing derivative L. salivarius UCC118Bac- (1 × 109 cfu/day). Data represented as mean ± SEM, n = 9–10. *p < 0.05](/cms/asset/e78ad9b0-fa43-48d0-bbf9-0751e6a75bf2/kgmi_a_10922328_f0002.gif)